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Background: Serious infections are common in patients undergoing autologous stem cell transplantation (ASCT)
mainly because of the effects of immunosuppression. The innate immune system plays an important role in the
defense against different infections. Mannose binding lectin (MBL) is a central molecule of the innate immune
system. There are several promoter polymorphisms and structural variants of the MBL2 gene that encodes for this
protein. These variants produce low levels of MBL and have been associated with an increased risk for infections.
Methods: Prospective cohort study. The incidence, severity of infections and mortality in 72 consecutive patients
with hematologic diseases who underwent ASCT between February 2006 and June 2008 in a tertiary referral center
were analyzed according to their MBL2 genotype. INNO-LiPA MBL2 was used for MBL2 gene amplification and
genotyping. Relative risks (RR) (IC95%) as measure of association were calculated. Multivariate analysis was
performed using logistic regression.
Results: A statistically significant higher number of fungal infections was found in patients with MBL2 variants
causing low MBL levels (21.1%versus1.9%, p=0.016). In this MBL2 variant group infection was more frequently the
cause of mortality than in the MBL2 wild-type group (p=0.05). Although not statistically significant, there was a
higher incidence of major infections in the MBL2 variant group as well as a higher number of infections caused by
gram-positive bacteria.
Conclusions: Low-producer MBL2 genotypes were associated with an increased number of fungal infections in
ASCT patients, which would suggest that MBL has a protective role against such infections. ASCT patients with
MBL2 variant genotypes are more likely to die as a result of an infection.
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Patients undergoing autologous stem cell transplantation
(ASCT) are at a high risk of serious infection, mainly due
to both the procedure and the underlying disease requir-
ing the transplant, which in most patients undergoing the
procedure is hematological [1-5].
Mannose-binding lectin (MBL) is a circulating liver-
synthesized C-type serum protein of importance in the* Correspondence: farinasc@unican.es
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tion molecules in the lectin complement activation
pathway [6]. Human MBL is derived from a single gene
located on chromosome 10 (MBL2) [3-8].
Serum levels and the function of MBL oligomers are
strongly influenced by genetic variants [9]. Low levels of
MBL have been associated with increased susceptibility to
infections, especially in recurrent or severe forms, even in
immunocompetent individuals [10]. However, isolated low
MBL serum levels do not usually cause disease. This defi-
ciency appears to be associated with severe infections when
other immune deficiencies occur [11].Ltd. This is an Open Access article distributed under the terms of the Creative
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tions of patients receiving chemotherapy is variable [11]. It
has been associated with serious infections and more pro-
longed episodes of febrile neutropenia [11-13], as well as
with an earlier first severe infection in deficient patients
[14]. There are also several studies which analyze the rela-
tionship between MBL and allogeneic stem cell transplant-
ation infections [15-22], but until now, only two studies
dealing with this issue in ASCT have been published
[23,24]. The focus of this study is the association between
MBL2 gene variants and the risk of infections in patients
with different hematologic diseases undergoing ASCT.
Patients and methods
Patients
A prospective cohort study of all patients who received an
ASCT for hematologic disease from February 2006 to June
2008 in the Hospital Universitario Marqués de Valdecilla
(1,000-bed teaching hospital) was performed. All trans-
planted patients >13 years old without immunodeficiency
(solid tumors, HIV infection or congenital immunodefi-
ciencies) were included. Patients were followed up after
inclusion in the study for 6 months.
Infections
Intercurrent infections were monitored during the early
period (0–30 days after ASCT), the intermediate period
(30–100 days after ASCT) and the late period (>100 days
after ASCT). Infections were prospectively collected by
the clinical research associates from the institution
using a standardized data collection form, following
the protocols of the Hematology Department of the
Hospital Universitario Marqués de Valdecilla, in compli-
ance with the clinical guidelines of the Infectious Diseases
Society of America [25]. Prophylactic measures included
isolation in high-pressure rooms with air filters and the
administration of intravenous acyclovir at prophylactic
doses from day −3. Antibiotics and antifungal prophylaxis
were not routinely administered.
An infectious episode was defined as a microbiologically
or clinically documented infection. Microbiologically docu-
mented infections with the same organisms during the
same phase of therapy occurring more than 7 days apart
were counted as different infections. Major infection was
predefined as either sepsis confirmed on microbiological
testing or a systemic inflammatory response syndrome with
highly suggestive radiographic or clinical characteristics and
the requirement for a specific antimicrobial treatment in
both cases. The following conditions were excluded: single
positive blood culture resulting from contaminant skin bac-
teria, upper respiratory tract infections, culture-negative
interstitial pneumonitis, dermatological varicella zoster re-
activation, and local herpes simplex reactivation. Severe
herpes virus infection was predefined as invasive viralinfections requiring prompt treatment and hospitalization.
A positive cytomegalovirus (CMV) blood culture or CMV-
pp65 antigenemia assay or polymerase chain reaction
(PCR) for CMV DNA (>400 copies/ml) (COBAS Amplicor
CMV Monitor, Roche Diagnostics) and symptoms of organ
dysfunction were required to fulfill the criteria of a clinically
significant CMV infection/reactivation [26]. Episodes of
asymptomatic CMV reactivation, primary varicella zoster
virus and Epstein-Barr virus infections were excluded.
MBL2 genotyping
Blood was collected in EDTA-stabilized tubes in compli-
ance with approved protocols from our institution. Gen-
omic DNA from patients and controls was extracted from
peripheral blood by using the Maxwell 16 Genomic DNA
Purification system. For MBL2 gene amplification and
genotyping, the INNO-LiPA MBL2 (Innogenetics Diagnos-
tica Iberia S.L.U, Barcelona, Spain) was used, following the
manufacturer’s instructions. The INNO-LiPA MBL2 is a
line probe assay, designed for genotyping the 6 variations
in the human MBL2 gene (−550G >C, −221G >C, +4C >
T, R52C, G54D, and G57E), providing an analysis of the
seven common haplotypes and the 28 possible resulting
diplotypes.
Exon mutations called structural variants (normal allele
or “wild-type” A and mutant alleles B, C and D which to-
gether were called allele O) and promoter polymorphisms
(H/L, Y/X and P/Q) were analyzed. Variants YA/YA, XA/
XA and YA/XA were classified as A/A. Those with any mu-
tation in the exon such as YA/O, XA/O were classified as
A/O and, lastly, individuals homozygous for the structural
variants in the exon were considered as O/O. Thus,
patients were divided in two groups according to their
MBL2 genotype: 1) normal homozygous patients (AA) and
2) patients with AO and OO genotypes, who were consid-
ered to be lower MBL producers [24].
Statistical analysis
Results were analyzed according to MBL2 genotype, com-
paring normal homozygous patients (AA) and patients with
AO and OO genotype and to determine if there were differ-
ences between the two groups in terms of demographic
characteristics, underlying disease, infection parameters
and mortality. Statistical analysis was performed using a
two-tailed χ2 test and a Fisher’s exact test, Student t-test or
Mann Whitney, as appropriate in each case. For m × n ta-
bles, a Fisher’s exact test was estimated using the Monte
Carlo method. Relative risks (RR) and their 95% confidence
intervals (CI) were calculated to analyze the association be-
tween genetic variants and polymorphisms and the risk of
concomitant infections as dependent variables (overall and
by microorganisms). Multivariate analysis was performed
using logistic regression to estimate the association between
genetic variants and polymorphisms and the risk of
Table 1 Characteristics and MBL genotypes of 72 patients
with ASCT
AA
Patients (%) n = 53
AO/OO
Patients (%) n = 19
P-value*
Gender
Male 30 (56.6) 12 (63.2) 0.62
Female 23 (43.4) 7 (36.8)
Mean age
(SD), years




MM 14 (26.4) 6 (31.6)
HD 8 (15.1) 5 (26.3)
NHL 22 (41.5) 7 (36.8)
AMN 7 (13.2) 1 (5.3)
PL 1 (1.9) 0
Amyloidosis 1 (1.9) 0
Active disease** 0.22
YES 11 (20.8) 7 (36.8)
NO 42 (79.2) 12 (63.2)
*Two-tailed Chi-squared test/Fisher exact test for categorical variables or two-
tailed t-test for continuous variables.
**Active pre-transplant hematologic disease.
MM: multiple myeloma, HD: Hodgkin disease, NHL: non Hodgkin lymphoma,
AMN: acute myeloid neoplasia, PL: prolymphocytic leukemia, ME:
multiple sclerosis.
AA genotype: patients homozygous for wild-type structural allele (A).
AO/OO genotype: patients heterozygous or homozygous for the B, C or D alleles.
Table 2 Number of chemotherapy lines pre-transplant
AA
Patients (%) n = 53
AO/OO
Patients (%) n = 19
P-value*
0 1 (1.9) 0 0.18
1 14 (26.4) 5 (26.3)
2 26 (49.1) 10 (52.6)
3 12 (22.6) 2 (10.5)
4 0 2 (10.5)
Mean (SD) 1.9 (0.8) 2.1 (0.9) 0.55
*Two-tailed Fisher’s exact test for categorical variables or two-tailed t-test for
continuous variables.
AA genotype: patients homozygous for wild-type structural allele (A).
AO/OO genotype: patients heterozygous or homozygous for the B, C or D alleles.
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gression model was constructed for each type of infection,
with infection-related variables being the outcome and the
independent variable being the MBL2 genotypes, adjusted
for sex, age, hematologic disease, active pre-transplant
hematologic disease. A two-tailed P <0.05 was considered
statistically significant. Data were analyzed using Stata (SE
10.0, Stata Corporation, College Station, TX) and SPSS
(version 19) (SPSS Inc., Chicago, IL) statistical software.
Ethics
This study was approved by the Ethics Committee of the
Autonomous Community of Cantabria, Spain. All pa-
tients (>18 years) signed informed consent to participate
in the study. For children under 18 years, the parents
had to sign informed consent.
Results
MBL2 structural variants, promoter polymorphisms and
genotypes
Seventy-two patients were included. Median age at the
time of transplantation was 54 years (19–74). During the
study period, no patients under 19 years underwent
AST. Forty-two (42) patients were men. Patients were
divided in two groups according to their MBL2 geno-
type: patients homozygous (AA) for wild type MBL2
(n = 53) and other patients, AO/OO (n = 19), which in-
cluded heterozygous patients (AO) (n = 16), and homo-
zygous patients (OO) (n = 3). No statistically significant
differences were found in both groups for gender, age,
distribution according to different types of hematologic
disease or hematologic disease activity at the time of
transplantation. Patient characteristics, underlying dis-
ease and number of previous lines of treatment are
shown in Tables 1 and 2.
Infections
Episodes of infection were recorded from the first day
after infusion (day +1) until the sixth month post-
transplantation. The average number of episodes of in-
fection per patient was 2 (SD = 1.3) with a minimum of
0 and a maximum of 8 (1 patient). A total of 138 epi-
sodes of infection were collected in 69 patients. Three
(3) patients had no infections during follow-up (4.2%).
Thirty-one (31) patients (43.1.%) had a single episode,
20 (27.8%) had 2 episodes, 11 (15.3%) 3 episodes, 4
(5.6%) 4 episodes, 2 (2.8%) 5 episodes and one patient
(1.4%) had 8 episodes of infection.
There were 112 infections in the early period (from day
1 to 30), 17 in the intermediate period (days 31 to 100)
and 9 in the late period (day 101 to the end of the study).
An average of 1.74 (SD = 1.04) episodes of infection oc-
curred in the wild-type MBL2 group, and 2.42 (SD = 1.84)
in the variant MBL2 group, with a greater number ofinfections in the deficient group (at the limit of statistical
significance, p = 0.051).
Table 3 shows infection characteristics. Sepsis was com-
mon (43.1%) and equally distributed between both groups,
as was urinary tract infection which occurred at a lower
frequency (11.1%) than expected. There was also a low in-
cidence of pneumonia (5.6% of all patients), which oc-
curred more frequently in the MBL2 variant group, 10.5%
versus 3.8%, RR: 2.8 (0.4-18.4), p = 0.28. Venous catheter
infection occurred at a similar rate in both groups; 11.3%
Table 3 MBL2 genotypes and infections in 72 patients with ASCT during the 6 months of follow-up
AA AO/OO RR (95% CI) P-value*
Patients (%) Patients (%)
n = 53 n = 19
Types of Infection
-Pneumonia 2 (3.8) 2 (10.5) 2.8(0.4-18.4) 0.28
-Sepsis 22 (41.5) 9 (47.4) 1.1 (0.6-2.0) 0.66
-VCI 6 (11.3) 2 (10.5) 0.9 (0.2-4.2) 1.00
-UTI 5 (9.4) 3 (15.8) 1.7 (0.4-6.3) 0.43
Major infection 6 (11.3) 5 (26.3) 2.32 (0.80-6.74) 0.15
Gram-positive infections 14 (26.4) 9 (47.4) 1.8 (0.9-3.4) 0.09
-S. epidermidis 9 (17) 7 (36.8) 2.2 (0.9-5.0) 0.11
-S. aureus 1 (1.9) 0 (0) – 1.00
-Other
Gram-negative infections 19 (35.8) 6 (31.6) 0.9 (0.4-1.9) 0.74
Viral infections 1 (1.9) 1 (5.3) 2.8 (0.2-42.4) 0.46
-CMV 0 (0) 1 (5.3) – 0.26
Fungal infections 1 (1.9) 4 (21.1) 11.5 (1.3-93.7) 0.016
-Candida 1(1.9) 2 (10.5) 5.6 (0.5-58.1) 0.17
-Aspergillus 0 (0) 1 (5.3) – 0.26
-Mucor 0 (0) 1 (5.3) – 0.26
Nº deaths 4 (7.5) 3 (15.8) 2.1 (0.5-8.5) 0.37
Cause of death
-Infection 0 3 – 0.05
-Progression 3 0 –
-Unknown (not infection) 1 0 –
*Two-tailed Chi-squared test or Fisher exact test as corresponding.
RR: risk ratio; CI: confidence interval.
VCI: Venous catheter infection; UTI: Urinary tract infection.
AA genotype: patients homozygous for wild-type structural allele (A).
AO/OO genotype: patients heterozygous or homozygous for the B, C or D alleles.
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Fifteen major episodes of infection were recorded:
sepsis in 8 patients; pneumonia in 5 patients, including
one pulmonary aspergillosis and one Mucor pneumo-
nia; and 2 patients with severe diarrheal episodes (one
caused by Clostridium difficile). A higher incidence of
major episodes of infection was observed in the variant
MBL2 group, 26.3% versus 11.3% in the MBL2 wild-type
group: RR = 2.32, (95% CI: 0.80-6.74, p = 0.15), although
this did not reach statistical significance.
There were 68 microbiologically documented infec-
tions (50% of all the infections) in 39 patients. Fifty-six
(82.4%) of these infections occurred in the early period,
5 (7.4%) in the intermediate and 7 (10.2%) in the late
period. There were 33 infections caused by gram-positive
bacteria, 36 caused by gram-negative bacteria, 5 fungal in-
fections and 2 infections caused by virus. Eight were poly-
microbial infections.The average number of microbiologically documented
infections was not statistically significant different be-
tween both groups, although there was a greater number
of infections with microbiological documentation in the
variant MBL2 group: 1.32 (SD = 1.53) versus 0.81 (SD =
0.96 p = 0.1).
There was a higher average of microbiologically docu-
mented episodes of infection in the early period in the
variant MBL2 group (1.90 (SD = 1.2), than in the MBL2
wild-type (1.37 (SD = 1.2 p = 0.062), but this did not reach
statistical significance.
The average time in days until the first infection after
the transplantation day was 7.98 days (SD = 11.34) in the
wild-type MBL2 group and 13 days (SD = 30.73) in the
MBL2 variant group (p = 0.32).
Regarding the type of infection, gram-positive bacteria
were more frequent in the MBL2 variant group, 47.4% ver-
sus 26.4%, RR = 1.8 (95% CI: 0.9-3.4, p = 0.09). There was
a greater incidence of infections caused by Staphylococcus
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RR = 2.2 (95% CI: 0.9-5.0, p = 0.11). In the adjusted ana-
lysis, the odds ratio (OR) was 4.0 (95% CI: 1.0-16.5, p =
0.05), at the limit of statistical significance (Table 4). There
was only 1 case of infection by Staphylococcus aureus, in
the MBL2 wild-type group.
Most infections caused by gram-positive bacteria oc-
curred in the early period and were more frequent in the
variant MBL2 group (42.1% versus 26.4% in the MBL2
wild-type group, p = 0.2). There were no such infections in
the intermediate period and only one in each group in the
late period.
The incidence of fungal infections in the variant MBL2
group (3 Candida albicans, 1Mucor, 1 Aspergillus) was sta-
tistically significantly higher than in the MBL2 wild-type
group (1 Candida spp), RR = 11.5 (95% CI: 1.3-93.7, p =
0.016), as confirmed in a multivariate analysis (Table 4).
There were no statistically significant differences in
the incidence of infection caused by gram-negative bac-
teria, RR: 0.9 (95% CI: 0.4-1.9, p = 0.74), or by virus be-
tween both groups, RR: 2.8 (95% CI: 0.2-42.4, p = 0.46),
although there was a higher incidence of viral infections
in the variant MBL2 group.
More patients died in the variant MBL2 group than
in the wild-type MBL2 group (15.8% versus 7.5% re-
spectively, p = 0.37), although this difference was not
statistically significant. However, all deaths in the vari-
ant MBL2 group were related to infection, whereas in
the wild-type MBL2 group, deaths were due to other
causes, with a p-value of 0.05 at the limit of statistical




OR* (95% CI) (Effect of MBL2
genotypes on risk of infection)
p-value
Types of infection
-Pneumonia 8.1 (0.4-158.2) 0.17
-Sepsis 0.9 (0.3-3.1) 0.88
-VCI 0.8 (0.1-5.0) 0.77
-UTI 2.3 (0.4-12.8) 0.44
Serious infection 0.8 (0.1-4.9) 0.79
Gram-positive infections 2.5 (0.8-7.5) 0.11
-S. epidermidis 4.0 (1.0-16.5) 0.05
Gram-negative infections 0.7 (0.2-2.4) 0.59
Viral infections 1.1 (0.01-60.4) 0.96
Fungal infections 12.9 (1.1-153.9) 0.03
*Odds Ratio (OR) adjusted by: sex, age, type of hematologic disease, active
pre-transplant hematologic disease.
CI: confidence interval.
VCI: Venous catheter infection; UTI: Urinary tract infection.Discussion
This prospective study focused on comparing the inci-
dence of infection and mortality after ASCT between pa-
tients with the wild-type MBL2 genotype compared to
patients carrying a variant MBL2 genotype. The MBL2
variant is associated with lower levels of serum MBL, so
it may be related with a greater number of infections
and/or more serious infections. A multivariate analysis
was performed to rule out other factors that could cause
a higher incidence or severity of infection (disease
status-response vs. type of hematologic disease, active
pre-transplant hematologic disease, sex and age).
The study group was homogeneous, with no differences
in age, gender or hematologic disease, and presented simi-
lar disease activity at the time of transplantation.
So far, there are few studies describing the incidence
of infections in ASCT related to MBL2 gene variants.
Horiuchi et al. [23] in a series of 113 patients treated
with high-dose chemotherapy and ASCT, most of whom
had hematologic diseases, carried out a study of the inci-
dence of major bacterial infection in patients with low-
producing genotypes compared to the wild-type genotype,
finding an association between the low-producing geno-
types and a highly increased and significant risk of major
bacterial infections. The incidence of major bacterial infec-
tions (9%) was lower than that observed in the current
study (18%). This could be related with the use of prophy-
lactic antimicrobials including ciprofloxacin and flucona-
zole in all their patients, in contrast to the usual practice
in our center.
Mølle et al. [24], in a retrospective study compared
MBL2 gene variants with the risk of severe infections in
multiple myeloma in patients receiving ASCT after high-
dose melphalan. They found that patients homozygous for
wild-type MBL2 had a significantly reduced risk of septi-
cemia compared to patients carrying the variant MBL2. In
our series, no differences were found in the number of pa-
tients with sepsis between the two groups. Although the
lack of association between these infections and MBL2 gene
variants could be explained by the sample size, this could
also be due to the different underlying diseases: in Mølle’s
study, all patients were diagnosed with multiple myeloma
while our patients had heterogeneous hematologic diseases
and therefore could have had a higher risk of infection.
They also found more severe infections in patients with
variantMBL2, although the differences were not statistically
significant. Similarly, in our series more severe infections
and a greater number of episodes of pneumonia were found
in patients with variant MBL2.
When the incidence of infections caused by different mi-
croorganisms was analyzed, a higher number of infections
caused by gram-positive bacteria was found in patients car-
rying the variant MBL2 form, and these were mainly
staphylococci. In this respect, the incidence of infections
Moreto et al. BMC Immunology 2014, 15:17 Page 6 of 7
http://www.biomedcentral.com/1471-2172/15/17caused by Staphylococcus epidermidis was greater in the
MBL2 variant group. These findings contrast with the simi-
lar number of central venous catheter infections found in
both groups. This could mean that the increased number
of infections caused by S. epidermidis is not only due to
catheter infection. ASCT patients carrying the variant
MBL2 genotype, with MBL deficiency, may develop more
S. epidermidis infections. However, the mechanism for this
difference is unclear. A study by Hellemann et al. [27] in
critically ill patients admitted to an intensive care, showed
an association between the MBL2 O/O genotype with an
increased incidence of gram-positive infections. However,
in two different studies by Neth et al. [28] and Shang et al.
[29], S. epidermidis generally demonstrated low MBL bind-
ing activity, which would contradict the hypothesis that
MBL plays an important role in infections caused by S. epi-
dermidis. One explanation that has been proposed for the
diversity between the different studies may rely on the fact
that MBL also functions as a scavenger molecule in main-
taining internal tissue homeostasis. Apparent MBL associa-
tions may be due to disturbances in this scavenger system,
rather than a direct antiinfectious effect [30].
In the current study, no differences were found in the
incidence of infections caused by gram-negative bacteria
in patients with wild-type MBL2 genotype versus patients
carrying a variant MBL2 genotype. This is consistent with
the studies by Hellemann [27] and Sutherland [31]. There
was only one case of viral infection in each group; in the
MBL2 variant group this was caused by CMV, a potentially
very serious disease, while the virus in the MBL2 wild-type
group was a reactivation of varicella zoster, which is more
common in hematological patients.
Granell et al. [18] showed that MBL pathway dysfunc-
tion due to genetically determined deficiencies of MBL
influence the outcome of allogenic stem cell transplant-
ation by increasing susceptibility to fungal invasive in-
fections. In patients with ASCT, Horiuchi et al. [23]
found that 3 of the 16 patients with major infections
who had a pulmonary aspergillosis were homozygous
for A, i.e. the normal MBL allele. On the contrary, in
our study, 4 patients with fungal infection carried the
MBL2 deficient genotype; 2 had Aspergillus and Mucor
pneumonia (both died as a consequence of their fungal
infection); 1 had candidemia; and 1 had disseminated
mucocutaneous Candida infection. Several studies have
been published showing that MBL may play a crucial
role in the innate immunity against yeast infections by
increasing PMN uptake [32,33].
In our series, the incidence of mortality due to infec-
tion was higher in the MBL2 variant form, and the
cause of death in all patients was major infection.
These findings are in line with other groups of immuno-
suppressed patients who had low-producing MBL2 geno-
types [27,34].Conclusions
In summary, the results of our study suggest that ASCT
patients with the MBL2 variant gene have increased fungal
infections, which would suggest that MBL offers protec-
tion against such infections. It would be reasonable to as-
sess whether early antifungal prophylaxis in our ASCT
patients with the MBL2 variant gene could reduce the in-
cidence of such infections. Due to the contradictory re-
sults of the previous reports, further studies are needed to
clarify whether low-producing MBL2 genotypes could play
a role in gram-positive infections, especially in S. epider-
midis infections. ASCT patients with MBL2 variant geno-
types are more likely to die as a result of an infection.
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